Assessment of long-term health effects of antimalarial drugs when used for prophylaxis /:
Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats tha...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, DC :
The National Academies Press,
[2020]
|
| Schriftenreihe: | Consensus study report.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events. |
| Beschreibung: | 1 online resource (1 PDF file (xvii, 407 pages)) : illustrations |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9780309672115 0309672112 9780309672139 0309672139 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1148889539 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr un||||||||| | ||
| 008 | 200602s2020 dcua obt 000 0 eng | ||
| 040 | |a NLM |b eng |e rda |e pn |c NLM |d EBLCP |d YDX |d N$T |d UKAHL |d OCLCF |d OCLCO |d NLM |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d K6U |d OCLCO |d OCLCQ |d PSYSI |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 101768402 |2 DNLM | |
| 019 | |a 1147904209 |a 1156664582 | ||
| 020 | |a 9780309672115 | ||
| 020 | |a 0309672112 | ||
| 020 | |a 9780309672139 |q (electronic bk.) | ||
| 020 | |a 0309672139 |q (electronic bk.) | ||
| 020 | |z 9780309672108 |q (paperback) | ||
| 020 | |z 0309672104 |q (paperback) | ||
| 035 | |a (OCoLC)1148889539 |z (OCoLC)1147904209 |z (OCoLC)1156664582 | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RC158 | |
| 060 | 0 | 0 | |a QV 256 |
| 082 | 7 | |a 166.9/362 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / |c David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division. |
| 264 | 1 | |a Washington, DC : |b The National Academies Press, |c [2020] | |
| 300 | |a 1 online resource (1 PDF file (xvii, 407 pages)) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a A consensus study report of the National Academies of Sciences, Engineering, Medicine | |
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events. | |
| 536 | |a This activity was supported by Contract Order No. VA 36C24E18C0067 between the National Academy of Sciences and the Department of Veterans Affairs. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | ||
| 588 | 0 | |a Online resource; title from PDF title page (viewed July 8, 2020). | |
| 505 | 0 | |a Intro -- FrontMatter -- Reviewers -- Preface -- Contents -- Acronyms and Abbreviations -- Summary -- 1 Introduction -- 2 Background -- 3 Identification and Evaluation of the Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6 Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9 Chloroquine -- 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs -- Appendix A: Public Meeting Agendas -- Appendix B: Invited Presentations -- Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria | |
| 650 | 0 | |a Malaria |x Evaluation. | |
| 650 | 0 | |a Malaria |x Diagnosis. | |
| 650 | 1 | 2 | |a Antimalarials |x adverse effects |0 https://id.nlm.nih.gov/mesh/D000962Q000009 |
| 650 | 1 | 2 | |a Antimalarials |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000962Q000627 |
| 650 | 2 | 2 | |a Long Term Adverse Effects |0 https://id.nlm.nih.gov/mesh/D000069451 |
| 650 | 2 | 2 | |a Malaria |x prevention & control |0 https://id.nlm.nih.gov/mesh/D008288Q000517 |
| 650 | 2 | 2 | |a Military Health |
| 651 | 2 | |a United States |0 https://id.nlm.nih.gov/mesh/D014481 | |
| 650 | 6 | |a Paludisme |x Évaluation. | |
| 650 | 7 | |a Malaria |x Diagnosis |2 fast | |
| 655 | 0 | |a Electronic books. | |
| 655 | 2 | |a Systematic Review |0 https://id.nlm.nih.gov/mesh/D000078182 | |
| 655 | 7 | |a Revues systématiques. |2 rvmgf | |
| 700 | 1 | |a Savitz, David A., |e editor. | |
| 700 | 1 | |a Styka, Anne N., |e editor. | |
| 710 | 2 | |a National Academies of Sciences, Engineering, and Medicine (U.S.). |b Committee to Review Long-Term Health Effects of Antimalarial Drugs, |e issuing body. |0 http://id.loc.gov/authorities/names/n2020184350 | |
| 758 | |i has work: |a Assessment of long-term health effects of antimalarial drugs when used for prophylaxis (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFBPBMHD9qjRphdxW4phpd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a National Academies of Sciences, Engineering, and Medicine. |t Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. |d Washington, D.C. : National Academies Press, ©2020 |
| 830 | 0 | |a Consensus study report. |0 http://id.loc.gov/authorities/names/n2017188206 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2490668 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH37414537 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6145682 | ||
| 938 | |a EBSCOhost |b EBSC |n 2490668 | ||
| 938 | |a YBP Library Services |b YANK |n 16761045 | ||
| 938 | |a YBP Library Services |b YANK |n 16711193 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1148889539 |
|---|---|
| _version_ | 1816882514519654400 |
| adam_text | |
| any_adam_object | |
| author2 | Savitz, David A. Styka, Anne N. |
| author2_role | edt edt |
| author2_variant | d a s da das a n s an ans |
| author_facet | Savitz, David A. Styka, Anne N. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC158 |
| callnumber-raw | RC158 |
| callnumber-search | RC158 |
| callnumber-sort | RC 3158 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Intro -- FrontMatter -- Reviewers -- Preface -- Contents -- Acronyms and Abbreviations -- Summary -- 1 Introduction -- 2 Background -- 3 Identification and Evaluation of the Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6 Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9 Chloroquine -- 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs -- Appendix A: Public Meeting Agendas -- Appendix B: Invited Presentations -- Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria |
| ctrlnum | (OCoLC)1148889539 |
| dewey-full | 166.9/362 |
| dewey-hundreds | 100 - Philosophy & psychology |
| dewey-ones | 166 - Syllogisms |
| dewey-raw | 166.9/362 |
| dewey-search | 166.9/362 |
| dewey-sort | 3166.9 3362 |
| dewey-tens | 160 - Philosophical logic |
| discipline | Philosophie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06124cam a2200745 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1148889539</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr un|||||||||</controlfield><controlfield tag="008">200602s2020 dcua obt 000 0 eng </controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NLM</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">NLM</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">N$T</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">NLM</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">PSYSI</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101768402</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1147904209</subfield><subfield code="a">1156664582</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309672115</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309672112</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309672139</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309672139</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309672108</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309672104</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1148889539</subfield><subfield code="z">(OCoLC)1147904209</subfield><subfield code="z">(OCoLC)1156664582</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">pcc</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC158</subfield></datafield><datafield tag="060" ind1="0" ind2="0"><subfield code="a">QV 256</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">166.9/362</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Assessment of long-term health effects of antimalarial drugs when used for prophylaxis /</subfield><subfield code="c">David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, DC :</subfield><subfield code="b">The National Academies Press,</subfield><subfield code="c">[2020]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (1 PDF file (xvii, 407 pages)) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">A consensus study report of the National Academies of Sciences, Engineering, Medicine</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.</subfield></datafield><datafield tag="536" ind1=" " ind2=" "><subfield code="a">This activity was supported by Contract Order No. VA 36C24E18C0067 between the National Academy of Sciences and the Department of Veterans Affairs. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (viewed July 8, 2020).</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- FrontMatter -- Reviewers -- Preface -- Contents -- Acronyms and Abbreviations -- Summary -- 1 Introduction -- 2 Background -- 3 Identification and Evaluation of the Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6 Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9 Chloroquine -- 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs -- Appendix A: Public Meeting Agendas -- Appendix B: Invited Presentations -- Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Malaria</subfield><subfield code="x">Evaluation.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Malaria</subfield><subfield code="x">Diagnosis.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Antimalarials</subfield><subfield code="x">adverse effects</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000962Q000009</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Antimalarials</subfield><subfield code="x">therapeutic use</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000962Q000627</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Long Term Adverse Effects</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000069451</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Malaria</subfield><subfield code="x">prevention & control</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D008288Q000517</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Military Health</subfield></datafield><datafield tag="651" ind1=" " ind2="2"><subfield code="a">United States</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D014481</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Paludisme</subfield><subfield code="x">Évaluation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Malaria</subfield><subfield code="x">Diagnosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="0"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Systematic Review</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000078182</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Revues systématiques.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Savitz, David A.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Styka, Anne N.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Academies of Sciences, Engineering, and Medicine (U.S.).</subfield><subfield code="b">Committee to Review Long-Term Health Effects of Antimalarial Drugs,</subfield><subfield code="e">issuing body.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2020184350</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Assessment of long-term health effects of antimalarial drugs when used for prophylaxis (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFBPBMHD9qjRphdxW4phpd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">National Academies of Sciences, Engineering, and Medicine.</subfield><subfield code="t">Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis.</subfield><subfield code="d">Washington, D.C. : National Academies Press, ©2020</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Consensus study report.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2017188206</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2490668</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH37414537</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6145682</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">2490668</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">16761045</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">16711193</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Electronic books. Systematic Review https://id.nlm.nih.gov/mesh/D000078182 Revues systématiques. rvmgf |
| genre_facet | Electronic books. Systematic Review Revues systématiques. |
| geographic | United States https://id.nlm.nih.gov/mesh/D014481 |
| geographic_facet | United States |
| id | ZDB-4-EBA-on1148889539 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:29:49Z |
| institution | BVB |
| institution_GND | http://id.loc.gov/authorities/names/n2020184350 |
| isbn | 9780309672115 0309672112 9780309672139 0309672139 |
| language | English |
| oclc_num | 1148889539 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (1 PDF file (xvii, 407 pages)) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | The National Academies Press, |
| record_format | marc |
| series | Consensus study report. |
| series2 | A consensus study report of the National Academies of Sciences, Engineering, Medicine |
| spelling | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division. Washington, DC : The National Academies Press, [2020] 1 online resource (1 PDF file (xvii, 407 pages)) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier A consensus study report of the National Academies of Sciences, Engineering, Medicine Includes bibliographical references. Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events. This activity was supported by Contract Order No. VA 36C24E18C0067 between the National Academy of Sciences and the Department of Veterans Affairs. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. Online resource; title from PDF title page (viewed July 8, 2020). Intro -- FrontMatter -- Reviewers -- Preface -- Contents -- Acronyms and Abbreviations -- Summary -- 1 Introduction -- 2 Background -- 3 Identification and Evaluation of the Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6 Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9 Chloroquine -- 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs -- Appendix A: Public Meeting Agendas -- Appendix B: Invited Presentations -- Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria Malaria Evaluation. Malaria Diagnosis. Antimalarials adverse effects https://id.nlm.nih.gov/mesh/D000962Q000009 Antimalarials therapeutic use https://id.nlm.nih.gov/mesh/D000962Q000627 Long Term Adverse Effects https://id.nlm.nih.gov/mesh/D000069451 Malaria prevention & control https://id.nlm.nih.gov/mesh/D008288Q000517 Military Health United States https://id.nlm.nih.gov/mesh/D014481 Paludisme Évaluation. Malaria Diagnosis fast Electronic books. Systematic Review https://id.nlm.nih.gov/mesh/D000078182 Revues systématiques. rvmgf Savitz, David A., editor. Styka, Anne N., editor. National Academies of Sciences, Engineering, and Medicine (U.S.). Committee to Review Long-Term Health Effects of Antimalarial Drugs, issuing body. http://id.loc.gov/authorities/names/n2020184350 has work: Assessment of long-term health effects of antimalarial drugs when used for prophylaxis (Text) https://id.oclc.org/worldcat/entity/E39PCFBPBMHD9qjRphdxW4phpd https://id.oclc.org/worldcat/ontology/hasWork Print version: National Academies of Sciences, Engineering, and Medicine. Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis. Washington, D.C. : National Academies Press, ©2020 Consensus study report. http://id.loc.gov/authorities/names/n2017188206 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2490668 Volltext |
| spellingShingle | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / Consensus study report. Intro -- FrontMatter -- Reviewers -- Preface -- Contents -- Acronyms and Abbreviations -- Summary -- 1 Introduction -- 2 Background -- 3 Identification and Evaluation of the Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6 Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9 Chloroquine -- 10 Improving the Quality of Research on the Long-Term Health Effects of Antimalarial Drugs -- Appendix A: Public Meeting Agendas -- Appendix B: Invited Presentations -- Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria Malaria Evaluation. Malaria Diagnosis. Antimalarials adverse effects https://id.nlm.nih.gov/mesh/D000962Q000009 Antimalarials therapeutic use https://id.nlm.nih.gov/mesh/D000962Q000627 Long Term Adverse Effects https://id.nlm.nih.gov/mesh/D000069451 Malaria prevention & control https://id.nlm.nih.gov/mesh/D008288Q000517 Military Health Paludisme Évaluation. Malaria Diagnosis fast |
| subject_GND | https://id.nlm.nih.gov/mesh/D000962Q000009 https://id.nlm.nih.gov/mesh/D000962Q000627 https://id.nlm.nih.gov/mesh/D000069451 https://id.nlm.nih.gov/mesh/D008288Q000517 https://id.nlm.nih.gov/mesh/D014481 https://id.nlm.nih.gov/mesh/D000078182 |
| title | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / |
| title_auth | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / |
| title_exact_search | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / |
| title_full | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division. |
| title_fullStr | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division. |
| title_full_unstemmed | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / David A. Savitz and Anne N. Styka, editors ; Committee to Review Long-Term Health Effects of Antimalarial Drugs, Board on Population Health and Public Health Practice, Health and Medicine Division. |
| title_short | Assessment of long-term health effects of antimalarial drugs when used for prophylaxis / |
| title_sort | assessment of long term health effects of antimalarial drugs when used for prophylaxis |
| topic | Malaria Evaluation. Malaria Diagnosis. Antimalarials adverse effects https://id.nlm.nih.gov/mesh/D000962Q000009 Antimalarials therapeutic use https://id.nlm.nih.gov/mesh/D000962Q000627 Long Term Adverse Effects https://id.nlm.nih.gov/mesh/D000069451 Malaria prevention & control https://id.nlm.nih.gov/mesh/D008288Q000517 Military Health Paludisme Évaluation. Malaria Diagnosis fast |
| topic_facet | Malaria Evaluation. Malaria Diagnosis. Antimalarials adverse effects Antimalarials therapeutic use Long Term Adverse Effects Malaria prevention & control Military Health United States Paludisme Évaluation. Malaria Diagnosis Electronic books. Systematic Review Revues systématiques. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2490668 |
| work_keys_str_mv | AT savitzdavida assessmentoflongtermhealtheffectsofantimalarialdrugswhenusedforprophylaxis AT stykaannen assessmentoflongtermhealtheffectsofantimalarialdrugswhenusedforprophylaxis AT nationalacademiesofsciencesengineeringandmedicineuscommitteetoreviewlongtermhealtheffectsofantimalarialdrugs assessmentoflongtermhealtheffectsofantimalarialdrugswhenusedforprophylaxis |